




Issue 2

NEWS Update

Cumulative Enrollment



The first THAOS site was activated in the US in December 2007 and enrolled 7 patients by the end of Jan 2008. Activation and enrollment was slow for most of 2008; however, the first half of 2009 has seen a rapid rise in activation and enrollment. Four sites, alone, were activated in May 2009!

20 Sites in 9 Countries Have Received Approval to Enroll Patients in THAOS

01. M. Maurer USA *¹
02. M. W-Cruz Brazil *²
03. S. Shah USA
04. J. Campistol Spain
05. D. Quan USA
06. I. Conceicao Portugal *³
07. O. Suhr Sweden
08. D. Cornblath USA
09. T. Coelho Portugal
10. E. Cupler USA
11. R. Witteles USA
12. S. Gottlieb USA
13. S. Ikeda Japan
14. T. Kyriakides Cyprus
15. W. Tang USA
16. D. Saperstein USA
17. B. PC Hazenberg Neth
18. R. Falk USA
19. H. Molgaard Denmark
20. J. Ralph USA


* Top 3 enrolling sites

- Site # 01 15 patients
- Site # 02 10 patients
- Site # 06 7 patients

2009 THAOS Poster Presentations

American Acad. of Neurology—April 2009
Peripheral Nerve Society— July 2009

Geographic Distribution of 53 patients enrolled in 12 sites in 6 Countries



Welcome to our New THAOS Scientific Board Chairperson: Teresa Coelho, MD

Teresa is the director of the FAP Clinic at the Hospital Santo Antonio in Porto, Portugal, where she has been treating ATTR patients since 1987. Teresa is highly published, and her work has dramatically expanded our knowledge of this disease. Her clinic sees over 500 patients per year.

Have problems entering data into the THAOS database?
Contact
support@THAOS.net

Have suggestions for improving the THAOS Database
Contact
bwhite@foldrx.com

TRIAL DEMOGRAPHICS: a snapshot of Registry progress

Baseline Characteristics

Baseline Data Available N = 41

Male = 32
Female = 9

Median Age 58.8 yrs
Male 60.7 yrs (Min/Max; 29.1/86.6)
Female 51.8 yrs (Min/Max; 33.5/71.0)


Race/Ethnicity
Caucasian 73.2%
African-American 12.2%
Latino-American 7.3%
Other 7.3%

(%) Post-Transplants at Baseline = 17 (41.4%)

Liver 14 (34.1%)
Kidney 1 (2.4%)
Heart 2 (4.9%)


On May 2, 2009, 50 patients were enrolled in THAOS, triggering the first data review and analysis. Signed data for 41 patients are summarized. The average age is 58.8, one quarter are women, and one third reported liver transplants at baseline.

TTR Data



Of the 41 patients enrolled, almost 50% have Val30Met, the most common mutation, followed by Wild-Type TTR.

Most Commonly Reported TTR-Related Symptoms



Pain/parasthesia topped the list of TTR-related neurologic symptoms with 43% of patients reporting this as the most common symptom. Heart failure was the most common cardiovascular symptom reported.


Submit Publication Proposals!

As the Registry grows, the more informative the data will become, and the more desirable the Registry will be as a study tool. Your active participation is crucial to achieving our common goal to find treatments and a cure for this disease. A major way to improve the quality of care for this patient population is through active publication of our findings. We encourage publication proposals to be submitted by all sites!



Visit the THAOS Website at www.THAOS.net and find information for patients, physicians/caregivers, and a password-protected section for THAOS investigators. Coming soon, THAOS investigators will have the opportunity to submit proposals for analysis/publication online once data are robust. Patients will be able to locate treatment centers near them, and physicians/caregivers can learn about the disease and how to become a THAOS site.

Our next **Goal**



September 2009